Outcomes of rechargeable sacral neuromodulation for faecal incontinence: A single‐centre observational study
Colorectal Disease · 2025
DOI: 10.1111/codi.70344 ↗At a glance
Beobachtungsstudie in Colorectal Disease, 2025. Written by Michael Okocha and 6 co-authors. Institution: Sir Alan Park's Physiology Unit, St Mark's the National Bowel Hospital, London, UK. Major MEDLINE topics: Fecal Incontinence, Electric Stimulation Therapy. 27 references. The full text is freely available (open access, CC BY 4.0).
Topics: Inkontinenz
Abstract (original language)
Introduction
Faecal incontinence (FI) remains a debilitating condition with considerable psychosocial burden. Rechargeable sacral neuromodulation (rSNM) systems offer extended battery longevity and MRI compatibility, potentially reducing surgical burden. However, real‐world data on their efficacy, safety and acceptability remain limited.
Method
This single‐centre observational cohort study evaluated 37 patients who received rSNM (InterStim™ Micro) for FI between August 2020 and August 2022. Patients completed validated questionnaires (St Mark's FI Score, Rockwood FIQOL, SF‐36) and a structured telephone interview assessing functional outcomes, adverse events and device satisfaction. Clinical records were reviewed for surgical and 3‐ to 5‐year follow‐up data.
Results
Median age was 63 years; 61% had a history of obstetric injury. Twenty‐eight patients received rSNM as a replacement for non‐rechargeable systems. Device satisfaction was low: 62% expressed regret and 96% reported challenges with charging. Connectivity issues affected 86% of patients. Six patients underwent device explantation and two required lead revision. Rockwood FIQOL and SF‐36 scores indicated persistent impairment in lifestyle, emotional well‐being and social functioning. Improvements in continence scores were modest and below expectations.
Conclusion
Despite theoretical advantages, rSNM provided limited clinical benefit in this cohort. High rates of dissatisfaction, management difficulties and surgical revisions raise concerns about its broader applicability. While the smaller device may suit select patients, non‐rechargeable systems with extended battery life may represent a more acceptable first‐line option. Further studies are needed to better define the role of rSNM in FI management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Sir Alan Park's Physiology Unit, St Mark's the National Bowel Hospital, London, UK.
- Institute of Continuing Education, Cambridge University, Cambridge, UK.
- Imperial College London, London, UK.
ORCID profiles: Michael Okocha, Carlotta La Raja
Cite
APA
Okocha, M., La Raja, C., Nikolaou, S., Cuthbert, H., Nasasra, A., Vaizey, C. J., & Thomas, G. P. (2025). Outcomes of rechargeable sacral neuromodulation for faecal incontinence: A single‐centre observational study. Colorectal Disease. https://doi.org/10.1111/codi.70344
Vancouver
Okocha M, La Raja C, Nikolaou S, Cuthbert H, Nasasra A, Vaizey CJ, et al. Outcomes of rechargeable sacral neuromodulation for faecal incontinence: A single‐centre observational study. Colorectal Disease. 2025. doi:10.1111/codi.70344
BibTeX
@article{Okocha2025,
author = {Okocha, Michael and La Raja, Carlotta and Nikolaou, Stella and Cuthbert, Hannah and Nasasra, Ahmad and Vaizey, Carolynne J and Thomas, Gregory P},
title = {Outcomes of rechargeable sacral neuromodulation for faecal incontinence: A single‐centre observational study},
journal = {Colorectal Disease},
year = {2025},
doi = {10.1111/codi.70344}
}
EUVIMED